GAFFX
Price
$87.97
Change
+$0.48 (+0.55%)
Updated
Sep 11 closing price
Net Assets
353.07B
VLLIX
Price
$49.73
Change
+$0.41 (+0.83%)
Updated
Sep 11 closing price
Net Assets
436.75M
Interact to see
Advertisement

GAFFX vs VLLIX

GAFFX vs VLLIX Comparison Chart in %
View a ticker or compare two or three
VS
GAFFX vs. VLLIX commentary
Sep 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GAFFX is a Buy and VLLIX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
GAFFX has more cash in the bank: 353B vs. VLLIX (437M). GAFFX pays higher dividends than VLLIX: GAFFX (0.51) vs VLLIX (0.00). GAFFX was incepted earlier than VLLIX: GAFFX (10 years) vs VLLIX (11 years). VLLIX (1.22) is less costly to investors than GAFFX (0.29). VLLIX is a more actively managed with annual turnover of: 38.00 vs. GAFFX (32.00). VLLIX has a lower initial minimum investment than GAFFX: VLLIX (100000) vs GAFFX (1000000). VLLIX annual gain was more profitable for investors over the last year : 4.52 vs. GAFFX (0.48). VLLIX (15.52) and GAFFX (14.95) have equivalent 5 years return.
GAFFXVLLIXGAFFX / VLLIX
Total Expense Ratio0.290.8833%
Annual Report Gross Expense Ratio0.291.2224%
Fund Existence10 years11 years-
Gain YTD9.30710.48789%
Front LoadN/AN/A-
Min. Initial Investment10000001000001,000%
Min. Initial Investment IRAN/AN/A-
Net Assets353B437M80,778%
Annual Yield % from dividends0.510.00-
Returns for 1 year0.484.5211%
Returns for 3 years44.5986.4652%
Returns for 5 years14.9515.5296%
Returns for 10 yearsN/A82.43-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KSPI99.892.74
+2.82%
Joint Stock Company Kaspikz American Depository Shares
GRBK68.420.92
+1.36%
Green Brick Partners
CGTX0.98N/A
+0.32%
Cognition Therapeutics
CTEV35.98-0.76
-2.07%
Claritev Corporation
CVKD1.09-0.09
-7.63%
Cadrenal Therapeutics Inc